跳至主要内容
临床试验/NCT07043790
NCT07043790已完成不适用

Radical Cystectomy Versus Tri-Modal Therapy for Treatment of cT2N0M0 Urinary Bladder Transitional Cell Carcinoma

Ain Shams University1 个研究点 分布在 1 个国家目标入组 73 人开始时间: 2021年4月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
73
试验地点
1
主要终点
Disease free survival

研究概览

简要总结

the aim of this study is to compare the oncological outcome of trimodal therapy with bladder preservation using maximal resection with chemoradiation versus the standard radical cystectomy for muscle invasive transitional cell carcinoma of urinary bladder.

详细描述

Bladder cancer is the 9th most common cancer in the world, accounting for approximately 5-8% of all male cancers which makes it the 4th most common cancer in men and accounts for approximately 2% of female cancers making it the 8th most common cancer among women .

Bladder cancer is the 2nd most common urogenital cancer; thus, it is considered a very frequent disease to deal with in urological practice .

The urinary bladder is lined internally with transitional epithelial cells (urothelium), followed by lamina propria which is formed of connective tissue supporting the overlying urothelium, then muscularis propria (detrusor muscle) followed by an outer layer called serosa .

Bladder cancer is usually presented by gross or microscopic hematuria (85-90%), it may be associated with irritative symptoms, especially in the presence of carcinoma in situ.

In advanced disease, the patient may complain of bone pain, loin pain, pain radiating to the buttocks and thighs, or even renal impairment due to obstruction of both lower ureters.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Adults of any gender, aged 18 years or older.
  • •Histologically confirmed urothelial (transitional cell) carcinoma (TCC) of the urinary bladder, clinical stage T2N0M0, diagnosed through:
  • •Imaging (CT or MRI).
  • •Cystoscopy.
  • •Biopsy and histopathological examination of the tumor.

排除标准

  • •Evidence of significant nodal involvement on imaging.
  • •Presence of carcinoma in situ (CIS).
  • •Hydronephrosis attributed to the bladder tumor.
  • •Non-TCC histology of bladder cancer.
  • •TCC with atypical histological variants including:
  • •Micropapillary,
  • •Plasmacytoid,
  • •Anaplastic, or
  • •Sarcomatoid variants.
  • •High-grade non-muscle invasive bladder cancer (NMIBC).
  • •Patients unfit for surgery.
  • •Patients unfit for chemotherapy or radiotherapy.
  • •Refusal to undergo randomization.
  • •Prior chemotherapy or radiotherapy for bladder cancer.

研究组 & 干预措施

Radical Cystectomy group

Active Comparator

Gtoup A : Radical cystectomy group Radical cystectomy included surgical removal of the bladder, adjacent organs, and regional lymph nodes. In males, it included removal of urinary bladder, prostate, and seminal vesicles whereas in females, it included removal of urinary bladder and reproductive organs (ovaries, fallopian tubes, uterus, and anterior vagina).

Standard pelvic lymph node dissection was performed to all patients in this group.

干预措施: Radical cystectomy with pelvic lymphadenectomy (Other)

Trimodal therapy group

Active Comparator

Group B : trimodal therapy group

the patients underwent maximal TURBT, where as much tumor as possible was completely resected using bipolar resectoscope. The goal was to remove all visible tumor including the underlying muscle layer and tumor edges.

This was followed by radio-sensitizing chemotherapy and radiotherapy..

Chemotherapy consisted of weekly administration of iv infusion of cisplatin (40mg/m2).

Radiotherapy delivered as EBRT aimed at delivering approximately 44- 46 Gy to the urinary bladder and pelvic lymphnodes.followed by additional boost to the bladder 54 GY and a final boost to the tumor 64-65 GY

干预措施: Trimodal therapy (Radiation)

结局指标

主要结局

Disease free survival

时间窗: 3 years

Cancer specific survival

时间窗: 3 years

Overall survival

时间窗: 3 years

次要结局

  • Complications of intervention(3 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ahmed Himdan Abdelhameed

Assistant Lecturer of Urology

Ain Shams University

研究点 (1)

Loading locations...

相似试验